Desk note · industry · Pharma / biotech
On 15 October 2026 Mankind Pharma agreed to acquire 70% of Belgium’s Armed Cell Therapeutics for €48 million through its Netherlands subsidiary, gaining experimental CAR-T programmes in blood and lung cancers.
On 15 October 2026, Mankind Pharma Ltd signed a definitive agreement to take a 70% stake in Armed Cell Therapeutics, a biotechnology company based in Belgium. The price is €48 million, to be invested through its Dutch subsidiary Mankind Pharma (Netherlands) B.V. ACTx researches chimeric antigen receptor T-cell therapies, which reprogramme a patient’s immune cells to attack cancer. Its pipeline includes programmes aimed at non-Hodgkin lymphoma and small cell lung cancer, diseases where standard options can run out quickly. Mankind’s earlier deals, including the 2024 acquisition of Bharat Serums and Vaccines, focused on marketed and near-market assets in India. This transaction is a bet on early science abroad.
CAR-T treatments have shown strong results in some blood cancers but remain expensive and complex to manufacture. Indian patients rarely access the latest cell therapies at scale because trials, plants, and payers sit overseas. Owning a platform company gives Mankind a seat at the lab bench rather than waiting for licensing talks years later. The science is still experimental. Regulators in Europe and India will want years of safety data before any therapy reaches hospitals. Mankind exports about 15% of revenue to Europe today, so the firm already knows those markets, yet R&D spend will rise before any product sales follow.
If you follow Indian pharma, compare this deal with peers who license oncology drugs instead of buying labs. Hospital chains and insurers should track whether any ACTx candidate eventually seeks trials in India, which could change high-cost cancer budgets. Employees and suppliers see management tilting capital toward innovation, not just branded generics. Watch closing conditions, how much extra EUR 50 million the board allowed for follow-on funding, and whether Mankind partners with a hospital chain for future clinical work.
Telecom / IPO
On 22 October 2026, exchange data showed Jio Platforms’ ₹30,213 crore issue had drawn about ₹3.73 lakh crore of total bids by late evening on Day 2, with the retail portion oversubscribed and market commentators citing diverted cash from other listed stocks during the book build.
SEBI / market infrastructure
On 22 October 2026, the Securities and Exchange Board of India proposed letting stock exchanges and depositories fund core-market and regulator-mandated initiatives without prior approval for each ticket, while keeping board oversight and financial safeguards and inviting comments until 12 November.
E-commerce / food delivery
On 22 October 2026, reporting said Flipkart is testing an internal food delivery product called Eat-in by Minutes with more than 8,000 employees in Bengaluru, using Ekart logistics as it prepares to compete with Zomato and Swiggy in meal delivery.
Digital trust / compliance
On 22 October 2026, eMudhra Ltd said its board will voluntarily withdraw from the global SSL/TLS certificate segment after a key-security incident on eight intermediate certificates, citing compliance cost and weak economics while stressing that other digital-trust services continue.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.